Advik Laboratories Ltd Stock Price Today (NSE: ADVIKLA)
Fundamental Score
Advik Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Advik Laboratories Ltd share price today is ₹1.65, up +0.00% on NSE/BSE as of 30 March 2026. Advik Laboratories Ltd (ADVIKLA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.36 (Cr). The 52-week high for ADVIKLA share price is ₹3.17 and the 52-week low is ₹1.57. The company has a Return on Equity (ROE) of -59.02% and a debt-to-equity ratio of 11.55.
Advik Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Advik Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Advik Laboratories Share Price: A Financial Stability Analysis
The pharmaceutical industry, known for its rigorous regulatory landscape and lengthy drug development cycles, often presents unique financial stability challenges for smaller players. This analysis examines the financial standing of Advik Laboratories Ltd, focusing on the current Advik Laboratories share price of ₹1.6799999475479126. A key concern is the absence of a Price-to-Earnings (PE) ratio, which typically signifies either negative earnings or a significant distortion in the market's valuation of the company.
A particularly concerning indicator is the Return on Capital Employed (ROCE) of -9.79%. This negative ROCE implies that Advik Laboratories is currently destroying value with its deployed capital. In practical terms, it suggests that for every rupee invested in the business, the company is losing nearly 10 paise. This severely impacts the company’s economic moat, hindering its ability to generate sustainable competitive advantages. A consistently negative ROCE can lead to erosion of shareholder equity and raises concerns about the long-term viability of the business model. Contrast this with companies like
Mankind Pharma Ltd, where perceived management quality and strategic execution often support robust profitability and capital allocation, potentially driving positive ROCE figures.When evaluating Advik Laboratories, it's helpful to consider its position relative to sector peers such as Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd. While each company operates within the same broader industry, their financial performance and operational efficiency can vary significantly. A deeper dive into these peer companies would involve comparing key metrics like revenue growth, profitability margins, and debt levels to benchmark Advik Laboratories' performance.
This analysis is a component of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra, focusing on observational insights into publicly available financial data. It does not offer any investment recommendations. The information presented should not be construed as financial advice and should be considered alongside other independent research before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Advik Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ADVIKLA across key market metrics for learning purposes.
Positive Indicators
0 factors identified
No significant strengths identified in current analysis.
Risk Factors
8 factors identified
Below-Average Return on Equity (-59.02%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-9.79%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Weak Earnings Growth (4.24% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (4.24% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Elevated Debt Levels (D/E: 11.55)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Negative Free Cash Flow (₹-5.33 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.58%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Advik Laboratories Ltd Financial Statements
Comprehensive financial data for Advik Laboratories Ltd including income statement, balance sheet and cash flow
About ADVIKLA (Advik Laboratories Ltd)
Advik Laboratories Ltd is a research-driven pharmaceutical company dedicated to developing, manufacturing, and marketing innovative and high-quality medicines. Focusing on therapeu...tic areas with unmet medical needs, Advik Laboratories strives to improve patient outcomes and enhance the quality of life for individuals worldwide. The company's state-of-the-art research and development facilities are staffed by a team of experienced scientists and researchers who are committed to discovering and developing novel drug formulations. Advik Laboratories adheres to the highest ethical standards and regulatory requirements, ensuring the safety and efficacy of its products. With a strong emphasis on innovation, quality, and patient-centricity, Advik Laboratories is poised to make a significant impact on the global healthcare landscape. The company's robust product portfolio encompasses a wide range of therapeutic categories, including cardiovascular diseases, diabetes, oncology, and infectious diseases. Advik Laboratories leverages advanced technologies and innovative drug delivery systems to develop differentiated products that address specific patient needs. The company's manufacturing facilities are equipped with advanced technology and adhere to strict quality control measures to ensure that all products meet the highest standards of purity, safety, and efficacy. Advik Laboratories is committed to providing affordable and accessible medicines to patients around the world, partnering with healthcare professionals and organizations to improve access to care and promote better health outcomes. Advik Laboratories has established a strong global presence, with a network of distributors and partners in key markets around the world. The company's commitment to innovation, quality, and patient-centricity has earned it a reputation as a trusted and reliable partner in the pharmaceutical industry. Advik Laboratories is constantly seeking to expand its product portfolio and explore new therapeutic areas to address emerging healthcare needs. The company is dedicated to improving the lives of patients worldwide through the development and delivery of innovative and high-quality medicines. Advik Laboratories is driven by a passion for science, a commitment to innovation, and a desire to make a positive impact on global healthcare.
Company Details
Key Leadership
ADVIKLA Share Price: Frequently Asked Questions
What is the current share price of Advik Laboratories Ltd (ADVIKLA)?
As of 30 Mar 2026, 12:07 pm IST, Advik Laboratories Ltd share price is ₹1.65. The ADVIKLA stock has a market capitalisation of ₹3.36 (Cr) on NSE/BSE.
Is ADVIKLA share price Overvalued or Undervalued?
ADVIKLA share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Advik Laboratories Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of ADVIKLA share price?
The 52-week high of ADVIKLA share price is ₹3.17 and the 52-week low is ₹1.57. These values are updated daily from NSE/BSE price data.
What factors affect the Advik Laboratories Ltd share price?
Key factors influencing ADVIKLA share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Advik Laboratories Ltd a good stock for long-term investment?
Advik Laboratories Ltd shows a 5-year Profit Growth of 4.24% and an ROE of -59.02%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 11.55 before investing in ADVIKLA shares.
How does Advik Laboratories Ltd compare with its industry peers?
Advik Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare ADVIKLA share price P/E of 0.00x and ROE of -59.02% against the industry averages to determine competitive standing.
What is the P/E ratio of ADVIKLA and what does it mean?
ADVIKLA share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is ADVIKLA performing according to Bull Run's analysis?
ADVIKLA has a Bull Run fundamental score of N/A/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ADVIKLA belong to?
ADVIKLA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Advik Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for ADVIKLA?
ADVIKLA has an ROE of -59.02%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Advik Laboratories Ltd generates profits from shareholders capital.
How is ADVIKLA debt-to-equity ratio and what does it indicate?
ADVIKLA has a debt-to-equity ratio of 11.55, which indicates high leverage that increases financial risk.
What is ADVIKLA dividend yield and is it a good dividend stock?
ADVIKLA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Advik Laboratories Ltd shares.
How has ADVIKLA share price grown over the past 5 years?
ADVIKLA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth 4.24%, and EPS Growth 4.24%.
What is the promoter holding in ADVIKLA and why does it matter?
Promoters hold 35.90% of ADVIKLA shares, with 16.04% pledged. High promoter holding often indicates strong management confidence in Advik Laboratories Ltd.
What is ADVIKLA market capitalisation category?
ADVIKLA has a market capitalisation of ₹3 crores, placing it in the Small-cap category.
How volatile is ADVIKLA stock?
ADVIKLA has a beta of N/A. A beta > 1 suggests the Advik Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ADVIKLA operating profit margin trend?
ADVIKLA has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is ADVIKLA quarterly performance?
Recent quarterly performance shows Advik Laboratories Ltd YoY Sales Growth of N/A% and YoY Profit Growth of 0.00%.
What is the institutional holding pattern in ADVIKLA?
ADVIKLA has FII holding of 0.00% and DII holding of 0.58%. Significant institutional holding often suggests professional confidence in the Advik Laboratories Ltd stock.